Arcturus Therapeutics Holdings Inc.
ARCT
$6.72
$0.172.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -58.04% | -39.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -58.04% | -39.40% | |||
| Cost of Revenue | 5.21% | -21.35% | |||
| Gross Profit | -182.63% | -378.40% | |||
| SG&A Expenses | 34.90% | 0.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.38% | -15.67% | |||
| Operating Income | -89.60% | -42.15% | |||
| Income Before Tax | -116.26% | -46.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -116.23% | -46.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -116.23% | -46.49% | |||
| EBIT | -89.60% | -42.15% | |||
| EBITDA | -94.46% | -45.33% | |||
| EPS Basic | -109.14% | -46.16% | |||
| Normalized Basic EPS | -109.19% | -46.22% | |||
| EPS Diluted | -109.14% | -46.16% | |||
| Normalized Diluted EPS | -109.19% | -46.22% | |||
| Average Basic Shares Outstanding | 3.40% | 0.22% | |||
| Average Diluted Shares Outstanding | 3.40% | 0.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||